Evidence for Adverse Phonatory Change Following an Inhaled Combination Treatment

Erickson, Elizabeth; Sivasankar, Mahalakshmi
February 2010
Journal of Speech, Language & Hearing Research;Feb2010, Vol. 53 Issue 1, p75
Academic Journal
Purpose: Voice problems are reported as a frequent side effect of inhaled combination (IC) treatments. The purpose of this experimental study was to investigate whether IC treatments are detrimental to phonation. We hypothesized that IC treatment would significantly increase phonation threshold pressure (PTP) and perceived phonatory effort (PPE), whereas sham treatment would not. Method: Fourteen healthy adults participated in a repeated-measures design in which they received IC and sham treatments in counterbalanced order. PTP and PPE were measured prior to treatments, immediately following treatments, and at 1 and 2 hr following treatments. Results: IC treatment increased PTP, but sham treatment did not. The increase in PTP was maintained for a 2 hr period following administration. PPE ratings were not significantly correlated with PTP. Conclusions: IC treatments can have acute, adverse effects on phonation. Detrimental phonatory effects were elicited in participants with no self-reported voice problems. IC treatments are being increasingly prescribed across the lifespan. The current data increase our understanding of the nature of phonatory deterioration associated with IC treatment and lay the groundwork for increased research effort to develop IC treatments that effectively control respiratory disease while minimizing an adverse effect on phonation.


Related Articles

  • Steroid or Steroid Plus Long-Acting Beta Agonist for Mild Persistent Asthma.  // Neurology Alert;May2011 Supplement, p1 

    The article discusses results of a study which showed that inhaled corticosteroids (ICS)/long-acting beta agonist (LABA) is superior to placebo than ciclesonide (CIC) in asthma control, referencing the report "Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate...

  • Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. Calverley, Peter M.A.; Anderson, Julie A.; Celli, Bartolome; Ferguson, Gary T.; Jenkins, Christine; Jones, Paul W.; Yates, Julie C.; Vestbo, Jørgen // New England Journal of Medicine;2/22/2007, Vol. 356 Issue 8, p775 

    Background: Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown. Methods: We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 μg plus fluticasone propionate...

  • Fluticasone propionate/prednisolone.  // Reactions Weekly;7/3/2010, Issue 1308, p18 

    The article describes several cases of pediatric patients who developed adrenal suppression while receiving treatment with fluticasone propionate, prednisolone and salmeterol/fluticasone propionate. Particular focus is given to their dosing regimen. The cortisol levels of a seven-month-old boy...

  • Weighing up risks in the use of LABAs. Upadhyay, Neil // GP: General Practitioner;2/16/2007, p35 

    The article assesses the risks involved in the use of long-acting beta-2 agonists (LABAs). LABAs should be used after a trial of low-dose inhaled corticosteroids and before the dose of inhaled corticosteroids is increased. LABAs are used to treat patients whose asthma is so severe that treatment...

  • Budesonide/Formoterol Turbuhaler®: A Review of its Use in Chronic Obstructive Pulmonary Disease. Scott, Lesley J. // Drugs;2012, Vol. 72 Issue 3, p395 

    Chronic obstructive pulmonary disease (COPD) is a highly heterogeneous, progressive inflammatory disease that imposes considerable economic and health-care burdens on society, with the disease predicted to remain a leading cause of mor-bidity and mortality worldwide in the future. Current...

  • Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy. Hanania, Nicola A.; Alpan, Oral; Hamilos, Daniel L.; Condemi, John J.; Reyes-Rivera, Irmarie; Jin Zhu; Rosen, Karin E.; Eisner, Mark D.; Wong, Dennis A.; Busse, William // Annals of Internal Medicine;5/3/2011, Vol. 154 Issue 9, p573 

    Background: Inhaled corticosteroids (ICS) and long-acting β2- agonists (LABAs) are recommended in patients with asthma that is not well-controlled; however, many patients continue to have inadequately controlled asthma despite this therapy. Objective: To evaluate the efficacy and safety of...

  • THE USE OF LONG-ACTING β2-AGONISTS AS MONOTHERAPY IN CHILDREN AND ADULTS. Camp, Pat G.; Tingting Zhang; Smith, M. Anne; Carleton, Bruce C. // Journal of Population Therapeutics & Clinical Pharmacology;2013, Vol. 20 Issue 1, pe1 

    Background In asthma, it is recommended that long-acting β2-agonists (LABAs) not be used as monotherapy, but, be used with inhaled corticosteroids (ICS) to minimize the risk of serious adverse events. Objective To test the hypothesis that if clinical recommendations were followed, LABA...

  • Asthma medication classes show similar AE rates.  // Reactions Weekly;11/21/2009, Issue 1279, p5 

    The article reports on two studies which investigated the rates of death, asthma-related adverse outcomes and hospitalizations in patients receiving long-acting beta2-agonists therapy as well as the pattern of hospitalization for myocardial infarction (MI) in patients taking asthma medications....

  • Adverse effects of long-term use of beta agonists. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;03/25/97, Vol. 10 Issue 3, p20 

    Reports that long-term administration of beta agonists may be associated with the development of tolerance and with increased airway responsiveness to allergen and to nonspecific stimuli. Recommendation for the use of inhaled steroids to counter the adverse effects of beta agonists.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics